EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab‐Refractory Multiple Myeloma Patients: A Multicenter Real‐World Study

Enrica Antonia Martino, Daniele Derudas, Elena Rossi, Paola Stefanoni, Silvia Mangiacavalli, Elena Zamagni, Massimo Offidani iD, Anna Furlan, Angela Maria Quinto, Roberta Della Pepa iD, Giuseppe Bertuglia iD, Emiliano Barbieri iD und 30 weitere

Hematological Oncology · 2025

DOI: 10.1002/hon.70042 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Hematological Oncology, 2025. Verfasst von Enrica Antonia Martino und 41 weiteren Autor:innen. Beteiligte Einrichtung: Department of Onco-hematology, Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy. Hauptthemen laut MEDLINE: Multiple Myeloma, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This multicenter real‐world analysis evaluated the efficacy of isatuximab, pomalidomide, and dexamethasone (IsaPd) in 51 patients with multiple myeloma (MM) who were refractory to daratumumab (Dara‐R). The majority were under 70 years old (60.8%), predominantly female (56.9%), and heavily pretreated, with 74.5% being triple‐class refractory (TCR); 32.1% of the 28 patients with cytogenetic data had high‐risk abnormalities. The overall response rate (ORR) was 56.9%, including 3 patients with stringent complete response (sCR), 4 with CR, and 7 with very good partial response (VGPR). Neither age, number of prior therapies, TCR status, nor time from Dara refractoriness to IsaPd initiation significantly affected response rates. Median progression‐free survival (PFS) was 5.8 months, with a 12‐month PFS probability of 30.6%. Baseline hemoglobin (Hb) levels were a key predictor of PFS: patients with Hb < 11.8 g/L had a 3.5‐fold increased risk of progression, with a median PFS of 4.6 months compared to 22 months in those with higher Hb. Median overall survival (OS) was 21.0 months, with a 12‐month OS probability of 63.4%. Lower Hb levels (< 11 g/L) were associated with a tenfold increased risk of mortality. Among the 28 patients who underwent FISH analysis, while no significant difference in mortality risk was observed, those with high‐risk cytogenetic abnormalities exhibited a nearly tenfold increased risk of disease progression. These results suggest that IsaPd offers a meaningful option for Dara‐R patients, with Hb levels serving as a critical predictor of both PFS and OS. However, PFS remains modest, underscoring the need for novel combination therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleDexamethasoneMaleAgedMiddle AgedThalidomidePrognosisAged, 80 and overAdultAntibodies, Monoclonal, HumanizedTreatment OutcomeSurvival RateDrug Resistance, NeoplasmAntibodies, Monoclonal

Stichwörter der Autor:innen

dara‐refractorydexamethasoneisatuximabmultiple myelomapomalidomidesalvage therapy

Substanzen

DexamethasonepomalidomideThalidomidedaratumumabisatuximabAntibodies, Monoclonal, HumanizedAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Onco-hematology, Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy.
  • Department of Hematology, Businco Hospital, Cagliari, Italy.
  • Section of Hematology, Catholic University, Fondazione Policlinico Gemelli IRCCS, Rome, Italy.
  • Hematology and Bone Marrow Transplant Unit, Bergamo, Italy.
  • Division of Hematology, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy.
  • IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.

ORCID-Profile: Massimo Offidani, Roberta Della Pepa, Giuseppe Bertuglia, Emiliano Barbieri, Cirino Botta, Giuseppe Mele, Antonella Bruzzese, Katia Mancuso, Loredana Pettine, Niccolò Bolli

Zitieren

APA

Martino, E. A., Derudas, D., Rossi, E., Stefanoni, P., Mangiacavalli, S., Zamagni, E., Offidani, M., Furlan, A., Quinto, A. M., Della Pepa, R., Bertuglia, G., Barbieri, E., Conticello, C., De Magistris, C., Bongarzoni, V., Cafro, A. M., Mele, A., Botta, C., Sgherza, N., …, & Gentile, M. (2025). Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab‐Refractory Multiple Myeloma Patients: A Multicenter Real‐World Study. Hematological Oncology. https://doi.org/10.1002/hon.70042

Vancouver

Martino EA, Derudas D, Rossi E, Stefanoni P, Mangiacavalli S, Zamagni E, et al. Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab‐Refractory Multiple Myeloma Patients: A Multicenter Real‐World Study. Hematological Oncology. 2025. doi:10.1002/hon.70042

BibTeX
@article{Martino2025,
  author = {Martino, Enrica Antonia and Derudas, Daniele and Rossi, Elena and Stefanoni, Paola and Mangiacavalli, Silvia and Zamagni, Elena and Offidani, Massimo and Furlan, Anna and Quinto, Angela Maria and Della Pepa, Roberta and Bertuglia, Giuseppe and Barbieri, Emiliano and Conticello, Concetta and De Magistris, Claudio and Bongarzoni, Velia and Cafro, Anna Maria and Mele, Anna and Botta, Cirino and Sgherza, Nicola and Mele, Giuseppe and Annibali, Ombretta and Rago, Angela and Fontana, Raffaele and Vigna, Ernesto and Bruzzese, Antonella and Mancuso, Katia and Amendola, Angela and Citro, Annalisa and Cotzia, Emilia and Morè, Sonia and Rivolti, Elena and Pettine, Loredana and Galli, Monica and De Stefano, Valerio and Petrucci, Maria Teresa and Corso, Alessandro and Neri, Antonino and Di Raimondo, Francesco and Bolli, Niccolò and Musto, Pellegrino and Morabito, Fortunato and Gentile, Massimo},
  title = {Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab‐Refractory Multiple Myeloma Patients: A Multicenter Real‐World Study},
  journal = {Hematological Oncology},
  year = {2025},
  doi = {10.1002/hon.70042}
}
Kostenlos starten →